OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...

Bone pain. Joint pain. Bone swelling. These are symptoms that about 1,000 people in the United States begin to feel each year ...

Alicia Ortstad, 19, from Uppsala, Sweden, was diagnosed with bone cancer in 2023, after suffering a series of symptoms she ...

The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

Early evidence suggests that certain epigenetic states and gene expression profiles could indicate whether a tumor is likely to metastasize, even at early stages before traditional methods can detect ...

A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...

A high degree of LOH across the genome predicts a lower survival probability. Our results have the potential of changing the clinical management of osteosarcoma by selecting those patients that ...

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive Phase 2b top-line data for ...